The spironolactone renaissance

Expert Opinion on Investigational Drugs

Volumn 10, Issue 5, 2001, Pages 943-954

  Doggrell, S A ^a   Brown, L ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Cardiac fibrosis; Clinical trials; RALES; Spironolactone

Indexed keywords

6BETA HYDROXY 7ALPHA THIOMETHYL SPIRONOLACTONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; ALDOSTERONE RECEPTOR; AMILORIDE; ANGIOTENSIN; ANTIANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; CANRENOIC ACID; COLLAGEN; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; GONADORELIN; LOOP DIURETIC AGENT; MESSENGER RNA; MINERALOCORTICOID; NORADRENALIN; OUABAIN; PLACEBO; POTASSIUM ION; POTASSIUM SPARING DIURETIC AGENT; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRIAMTERENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACNE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; DRUG STRUCTURE; EPITHELIUM CELL; FEMALE; FIBROSIS; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HIRSUTISM; HOSPITALIZATION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; KIDNEY EPITHELIUM; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PRECOCIOUS PUBERTY; RANDOMIZED CONTROLLED TRIAL; RAT; SURVIVAL; VASODILATATION;

ALDOSTERONE; ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; COLLAGEN; HEART FAILURE, CONGESTIVE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; SPIRONOLACTONE;

EID: 0035016864     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.5.943     Document Type: Article

References (50)

1. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: A longitudinal study
2. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in heart failure?
3. Primary aldosteronism
4. Primary aldosteronism: Learning from the study of familial varieties
5. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: Mechanistic evidence to support RALES
6. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat
7. Induction of cardiac fibrosis by aldosterone
8. Left ventricular fibrosis in renovascular hypertensive rats. Effects of losartan and spironolactone
9. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system
10. Angiotensin AT1 receptor subtype as cardiac target of aldosterone: Role in aldosterone-salt-induced fibrosis
11. Activation of cardiac production in rat myocardial infarction: Effect on angiotensin II receptor blockade and role in cardiac fibrosis
12. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats
13. Extra-adrenal mineralocorticoids and cardiovascular tissue
14. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
15. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
16. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo
17. Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate
18. Effect of spironolactone and its metabolites on contractile poperty of isolated rat aorta rings
19. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation
20. Aldosterone and spironolactone in heart failure
21. Aldosterone escape during ACE inhibitor therapy in chronic heart failure
22. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
23. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
24. Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure
25. Aldosterone and vascular damage
26. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
27. ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES)
28. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
29. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
30. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES)
31. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
32. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure
33. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy
34. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppressed vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
35. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure
36. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor
37. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension
38. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites
39. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo
40. Comparison between theophylline and spironolactone in the management of cirrhotic ascites: A randomised controlled study
41. Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients
42. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: A ramdomized, double blind, placebo-controlled trial
43. Spironolactone as a single agent for long-term therapy of hirsute patients
44. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
45. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset
46. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
47. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
48. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
50. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial